C20D(3)-Vitamin A Prevents Retinal Pigment Epithelium Atrophic Changes in a Mouse Model

PURPOSE: This study aimed to evaluate the contribution of vitamin A dimerization to retinal pigment epithelium (RPE) atrophic changes. Leading causes of irreversible blindness, including Stargardt disease and age-related macular degeneration (AMD), occur as a result of atrophic changes in RPE. The cause of the RPE atrophic changes is not apparent. During the vitamin A cycle, vitamin A dimerizes, leading to vitamin A cycle byproducts, such as vitamin A dimers, in the RPE. METHODS: To study the consequence of vitamin A dimerization to RPE atrophic changes, we used a rodent model with accelerated vitamin A dimerization, Abca4(−/−)/Rdh8(−/−) mice, and the vitamin A analog C20D(3)-vitamin A to selectively ameliorate the accelerated rate of vitamin A dimerization. RESULTS: We show that ameliorating the rate of vitamin A dimerization with C20D(3)-vitamin A mitigates pathological changes observed in the prodromal phase of the most prevalent retinal degenerative diseases, including fundus autofluorescence changes, dark adaptation delays, and signature RPE atrophic changes. CONCLUSIONS: Data demonstrate that the dimerization of vitamin A during the vitamin A cycle is sufficient alone to cause the prerequisite RPE atrophic changes thought to be responsible for the leading causes of irreversible blindness and that correcting the dimerization rate with C20D(3)-vitamin A may be sufficient to prevent the RPE atrophic changes. TRANSLATIONAL RELEVANCE: Preventing the dimerization of vitamin A with the vitamin A analog C20D(3)-vitamin A may be sufficient to alter the clinical course of the most prevalent forms of blindness, including Stargardt disease and age-related macular degeneration (AMD).